Also - Ryan is on the job market for a PI position (walshr1@mskcc.org), so if your department is interested in hiring someone who will be a leader in next generation human PSC-based CNS disease modeling for neuropsychiatric disorders such as SCZ, he is a brilliant choice!

Ryan’s paper out in Neuron (bit.ly/3IICGFX). He derived bona fide parvalbumin (PV+) cortical interneurons from hPSCs, one the slowest developing neurons, and could capturing interneuron-related disease phenotypes linked to schizophrenia - including impaired gamma-oscillations - in his assembloids.

Exciting news from BlueRock Therapeutics & Bayer on upcoming phase III trial for our DA neuron cell therapy in Parkinson’s disease. www.bluerocktx.com/bluerock-the...

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial - BlueRock Therapeutics LP

BlueRock will initiate a Phase III clinical trial for bemdaneprocel, its investigational cell therapy for Parkinson’s disease. It is expected to begin in the first half of 2025 and will represent a si...

bluerocktx.com